Rafferty Asset Management LLC Sells 136,198 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Rafferty Asset Management LLC reduced its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 36.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 234,836 shares of the biotechnology company's stock after selling 136,198 shares during the period. Rafferty Asset Management LLC owned about 0.11% of BioCryst Pharmaceuticals worth $1,766,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in BCRX. Venturi Wealth Management LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $46,000. R Squared Ltd acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $48,000. KBC Group NV boosted its position in BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after buying an additional 4,537 shares in the last quarter. Raymond James Financial Inc. acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $80,000. Finally, Syon Capital LLC acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $99,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $13.00 target price (up from $11.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price target for the company. Barclays boosted their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday. Finally, JPMorgan Chase & Co. increased their target price on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $16.56.

BioCryst Pharmaceuticals Trading Up 1.9%

Shares of NASDAQ:BCRX traded up $0.20 on Friday, reaching $10.59. 3,608,168 shares of the company's stock were exchanged, compared to its average volume of 3,022,861. The company has a fifty day moving average of $8.38 and a 200-day moving average of $8.05. BioCryst Pharmaceuticals, Inc. has a twelve month low of $5.92 and a twelve month high of $11.11. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of -17.36 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. The company's quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.28 EPS. As a group, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.